Abstract: Pharmaceutical compositions are described, the compositions comprising therapeutically effective quantities of compounds (such as mycophenolic acid or cyclosporine) that are capable of treating, preventing, and/or or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical kits and use of the kits in the treatment of conditions of the eye, such as dry eye disease, which includes a first composition including a corticosteroid, an immunosuppressant or both a corticosteroid and an immunosuppressant in a pharmaceutically acceptable carrier configured for administration to a subject’s eyes; a second composition including a corticosteroid in a pharmaceutically acceptable carrier configured for administration to a subject’s eyes, where the second composition has a higher concentration of corticosteroid than the first composition; and optionally a lubricating formulation that is pharmaceutical-free. Treatment of dry eye disease includes administering topically to the eyes of a subject suffering from chronic dry eye disease the first composition over a treatment period; and if the subject suffers from an episodic flare up during the treatment period, administering the second composition to substantially alleviate the flare-up.

Abstract: Pharmaceutical compositions and methods for treating ocular disorders in a subject, which include betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% w/w to 0.08% w/w, mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% w/w to 0.30% w/w, or both betamethasone and mycophenolic acid or their salts.

Abstract: Pharmaceutical compositions including betamethasone sodium phosphate and mycophenolic acid and their use in the treatment of ocular surface disease.

Abstract: Pharmaceutical compositions are described, the compositions comprising an immunosuppressant (such as mycophenolic acid) in combination with a very low concentration of a corticosteroid (such as betamethasone) that are capable of treating, preventing, and/or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.

Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: Pharmaceutical compositions are described, the compositions comprising therapeutically effective quantities of compounds (such as mycophenolic acid or cyclosporine) that are capable of treating, preventing, and/or or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.

Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Abstract: Methods of treating a subject suffering from an ocular infection and/or ocular inflammation are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least two active agents in an ophthalmically acceptable vehicle that can provide a sustained release of the at least two active agents. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.

Abstract: Methods of treating a subject suffering from an ocular infection and/or ocular inflammation are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least two active agents in an ophthalmically acceptable vehicle that can provide a sustained release of the at least two active agents. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.

Abstract: Methods of treating a subject after ocular surgery are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.

Abstract: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

Abstract: A method of treating a recurring meibomian gland disorder in a patient includes administering to a patient suffering from recurring meibomian gland disorder a composition comprising a therapeutically effective amount of an azalide antibiotic and a glucocorticoid. The method may thereby reduce the frequency of recurrence of the meibomian gland disorder.

Abstract: Provided are method and kits useful for extending the wear-time of a contact lens. The method includes applying an amount of an ophthalmically acceptable solution to the contact lens to improve the comfort of the eye when the contact lens is in the eye. The solution includes an aqueous suspension and chitosan. The aqueous suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. Upon contact with tear fluid, the solution gels to a second viscosity which is greater than the first viscosity. The kit includes contact lenses, an ophthalmically acceptable solution and instructions for applying the solution to improve the comfort of the eye when the contact lens is in the eye.

Abstract: Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.